Compliance Rate
Compliance Rate
0%
Compliant submissions
0
Incompliant submissions
0
Total trials
0
My Organizations' Clinical Trials
Showing 325 of 545 entries
View as:
Phase: N/A
Priority: Normal
Start: 11/01/23
End: 06/30/27
Due: 06/30/28
Phase: N/A
Priority: Normal
Start: 04/06/20
End: 12/31/23
Due: 12/31/24
Phase: N/A
Priority: Normal
Start: 01/01/14
End: 04/30/20
Due: 04/30/21
Phase: N/A
Priority: Normal
Start: 05/31/15
End: 05/31/17
Due: 05/31/18
Phase: N/A
Priority: Normal
Start: 10/31/06
End: 06/30/09
Due: 06/30/10
Phase: N/A
Priority: Normal
Start: 06/30/10
End: 03/31/11
Due: 03/31/12
Phase: N/A
Priority: Normal
Start: 01/31/09
End: 12/31/11
Due: 12/31/12
Phase: N/A
Priority: Normal
Start: 10/31/11
End: 06/30/16
Due: 06/30/17
Phase: N/A
Priority: Normal
Start: 02/23/23
End: 08/13/23
Due: 08/13/24
Phase: N/A
Priority: Normal
Start: 11/15/18
End: 12/13/18
Due: 12/13/19
Phase: N/A
Priority: Normal
Start: 11/30/11
End: 02/28/13
Due: 02/28/14
Phase: N/A
Priority: Normal
Start: 02/27/17
End: 05/31/18
Due: 05/31/19
Investigation of Association Between UGT1A1 Polymorphisms and Irinotecan Toxicity in Korean Patients
Phase: N/A
Priority: Normal
Start: 01/31/09
End: 12/31/19
Due: 12/31/20
Phase: N/A
Priority: Normal
Start: 05/15/17
End: 11/15/22
Due: 11/15/23
Phase: N/A
Priority: Normal
Start: 08/31/15
End: -
Due: -
Phase: N/A
Priority: Normal
Start: 12/31/14
End: 10/31/16
Due: 10/31/17
Phase: N/A
Priority: Normal
Start: 01/31/10
End: 12/31/15
Due: 12/31/16
Phase: N/A
Priority: Normal
Start: 12/06/19
End: 10/31/20
Due: 10/31/21
Phase: N/A
Priority: Normal
Start: 02/28/15
End: 12/31/15
Due: 12/31/16
Phase: N/A
Priority: Normal
Start: 01/31/14
End: 02/28/14
Due: 02/28/15
Phase: N/A
Priority: Normal
Start: 02/20/20
End: 06/30/29
Due: 06/30/30
Phase: N/A
Priority: Normal
Start: 03/22/21
End: 12/31/23
Due: 12/31/24
Phase: N/A
Priority: Normal
Start: 12/31/12
End: 01/31/13
Due: 01/31/14
Phase: N/A
Priority: Normal
Start: 09/30/11
End: -
Due: -
Phase: N/A
Priority: Normal
Start: 08/13/20
End: 06/30/22
Due: 06/30/23